Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer

Inclusion Criteria: 1. Male or female aged 18-75 years (inclusive); 2. Understands and voluntarily signs a written informed consent form, and is willing and able to comply with all trial requirements; 3. Patients with advanced gastric cancer and advanced pancreatic cancer confirmed by histopathology or cytology, who have failed standard treatment or cannot tolerate standard treatment, including but not limited to: pancreatic cancer and gastric cancer; 4. Immunohistochemical (IHC) detection of CLDN18.2, the positive expression of CLDN18.2 in tumors must be ≥ 10%; 5. At least 1 measurable lesion according to RECIST 1.1; 6. ECOG score is 0-1; 7. All toxic reactions caused by previous antineoplastic therapy were resolved to grade 0-1 (according to NCI CTCAE 5.0 edition); Expected survival ≥ 12 weeks; In addition to the primary disease, no serious hematology, heart and lung, liver and kidney disease, laboratory tests meet the following requirements: Peripheral blood neutrophil absolute value ≥ 2000/mm3, platelet ≥ 50000/mm3 Serum creatinine ≤ 1.5mg/dL;ALT (alanine aminotransferase)/AST (aspartate aminotransferase) below 2.5 times the upper limit of normal; Total bilirubin ≤ 1.5mg/dL; Cardiac ejection fraction (EF)≥ 50%; International standard ratio (INR) or prothrombin time (PT) below 1.5 times the upper limit of normal; Activated partial coagulation time (aPTT) below 1.5 times the upper limit of normal; 10. Women of childbearing potential must have a negative serum pregnancy test and agree to effective birth control during the treatment phase and within 12 months after injection of CAR-NK cells; Male patients must agree to use effective birth control during the study and for 12 months after injection of CAR-NK cells. Exclusion Criteria: 1. History of other tumors; 2. Patients who have received CAR-T,CAR-NK,TCR-T and other cell therapy targeting Claudin18.2 within 3 months before study treatment; 3. Patients with hypersensitivity to cell therapy or any related drugs; 4. Active autoimmune diseases; 5. Active infections that cannot be controlled; 6. HIV infection, uncontrolled HBV, HCV and syphilis infections; 7. Have metastatic disease of the central nervous system (CNS), leptomeningeal disease or spinal cord compression; 8. Patients with severe heart disease; 9. Patients with unstable/active ulcers or bleeding from the digestive system; 10. Patients with a history of bleeding or bleeding tendency in the digestive system; 11. Pregnant or lactating women; 12. There are other factors that the researcher believes are not suitable for participating in the trial.